<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neuroinflammation caused by microglial activation plays a key role in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> and many other <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> diseases </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we found that Adjudin, a potential non-hormonal male contraceptive, exhibits additional function to reduce the production of proinflammatory mediators </plain></SENT>
<SENT sid="2" pm="."><plain>Adjudin significantly inhibited LPS-induced IL-6 release and IL-6, IL-1β, TNF-α expression in BV2 microglial cells </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, Adjudin exhibited anti-inflammatory properties by suppression of NF-κB p65 nuclear translocation and DNA binding activity as well as ERK MAPK phosphorylation </plain></SENT>
<SENT sid="4" pm="."><plain>To determine the in vivo effect of Adjudin, we used a permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (pMCAO) mouse model and found that Adjudin could reduce <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced CD11b expression, a marker of microglial activation </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, Adjudin treatment attenuated <z:hpo ids='HP_0002181'>brain edema</z:hpo> and neurological deficits after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> but did not reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, our data suggest that Adjudin may be useful for mitigating neuroinflammation </plain></SENT>
</text></document>